Adrian Gore

Who Adrian Gore is

Adrian Gore is an actuary who founded Discovery in 1992 and still runs it. Discovery now administers the largest private health insurance operation in South Africa, owns a bank, and licenses a behavioural-incentive model to insurers in the United States, the United Kingdom, China and Singapore.

In the 2025 financial year the group reported revenue of R37.03 billion, net income of R9.55 billion and total assets of R327.45 billion. It trades on the JSE as DSY.

An actuary, not a salesman

Gore was born on 16 May 1964 and took a Bachelor of Science in actuarial science at the University of the Witwatersrand. He is a Fellow of the Actuarial Society of South Africa and of the Faculty of Actuaries in Edinburgh, an associate of the Society of Actuaries in Chicago, and a member of the American Academy of Actuaries.

He started at Liberty Life as a trainee actuary in 1986 and went on to lead product development there. That is the whole of his employment history before he started his own company at twenty-eight.

The training matters more here than on most pages of this index. Insurance is a business in which the product is a promise about a probability distribution, and the person who understands the distribution has an advantage over the person selling the promise. Almost everything distinctive about Discovery is an actuarial idea before it is a marketing one.

1992, and who paid for it

Discovery was founded in 1992 by Gore and Barry Swartzberg as a medical insurer. The seed capital came from Laurie Dippenaar and other funders who had founded Rand Merchant Bank.

That detail is worth dwelling on, because it recurs across this index. The RMB circle did not simply make money in banking; it funded other people who then made money elsewhere. Discovery is the clearest example — an entire insurance group, now worth more than three hundred billion rand in assets, capitalised by a handful of bankers backing a twenty-eight-year-old actuary with an idea. Two of the founders and their backer all appear on this index separately.

The idea: pay people to be healthier

The insight underneath Discovery is simple to state and was genuinely novel to implement.

A conventional health insurer is a passive payer. It prices the risk that you will get ill, collects premiums, and settles claims. It has no mechanism for changing the thing it is pricing, so its only levers are underwriting more carefully and paying out less.

Gore’s proposition was that an insurer could instead alter the risk it had underwritten — that if you reward members for exercising, eating better and having screenings, enough of them change behaviour to reduce claims by more than the rewards cost. If that holds, the insurer and the member both gain, which is an unusual thing in insurance, where the two sides are normally in a zero-sum relationship over every claim.

That is the Vitality model, and it became the group’s exportable asset. Discovery does not need to be the insurer in a foreign market to earn from it; it can license the behavioural engine to somebody who already is.

What the group actually consists of

Four South African businesses and a set of international stakes.

Discovery Health administers medical schemes and sells specialised medical insurance. As at December 2025 it covered 1.36 million main members and 2.72 million dependants — close to four million people, and almost 60 per cent of the South African private health insurance market. Discovery Life sells life and long-term insurance. Discovery Insure sells motor, household and other short-term cover. Discovery Bank launched in March 2019, describing itself as the world’s first behavioural bank — the same model applied to money rather than health.

Internationally the group owns VitalityHealth and VitalityLife in the United Kingdom outright, 75 per cent of The Vitality Group in Chicago, 50 per cent of AIA Vitality in Singapore as a joint venture with the AIA Group, 25 per cent of Ping An Health in China and 25 per cent of HumanaVitality in Kentucky.

Sixty per cent of a national private health market is the number to sit with. It is the kind of position that attracts competition authorities, and it means Discovery’s commercial decisions are close to being health policy for a large share of insured South Africans.

Does the model actually work?

The honest answer is that it is genuinely difficult to prove, and the difficulty is instructive rather than damning.

The claim is that rewarding healthy behaviour reduces claims by more than the rewards cost. Testing it properly would require knowing what the same members would have cost without the incentives, which is unobservable. And the people who join a gym-rewards programme and use it are, on average, people who were already going to look after themselves — so a straightforward comparison of engaged and unengaged members measures who they were before they joined at least as much as what the programme did to them.

There is a second, commercially powerful effect that works whether or not the behavioural claim holds. A scheme that is attractive to fit, health-conscious people will attract fit, health-conscious people. That improves the risk pool regardless of whether anyone’s behaviour changed, because the insurer has selected a better population rather than improved the one it had. It is a real advantage and a durable one; it is simply not the same thing as making the country healthier.

Both effects put money in the same place, which is why the model has been licensed by insurers on four continents. A reader should hold the commercial success and the public-health claim separately, because the evidence for the first is overwhelming and the evidence for the second is contested.

What sixty per cent of a market means

Discovery Health covers almost 60 per cent of the South African private health insurance market. That position has consequences a reader of this site is more likely to encounter than any share price.

It means the administrator’s decisions — which procedures are funded, which hospital networks are in or out, how a plan’s benefits are structured — effectively set the terms for a large majority of privately insured South Africans. There is competition, but for many employers and members the practical choice is between Discovery plans rather than between insurers.

It also means the group is unavoidably a participant in health policy rather than an observer of it. Any reform of how South Africa funds healthcare runs through an institution this size, and the group’s commercial interest in the outcome is very large. None of that is a criticism; it is the position that success in this particular market produces.

How Rateweb values him

Gore is among the better-evidenced entries here. Discovery is JSE-listed, he is an executive director, and directors’ beneficial interests are disclosed in the annual report under the JSE’s listing requirements. Discovery is also one of the twelve companies for which this index holds a market capitalisation, so his listed stake revalues from a price rather than sitting frozen — see the methodology.

His entry carries a disclosed Discovery shareholding plus an estimate for private investments. The first half is reproducible; the second is not, and it is where the uncertainty sits.

One structural caveat applies to this entry more than most. A founder-chief-executive’s holding is frequently not all freely held: portions may be subject to vesting, lock-ins, or option schemes not yet exercised. A headline stake and a disposable stake are different quantities, and where the disclosure does not distinguish them, neither do we.

The awards, and what they are worth

Gore was named South Africa’s best entrepreneur by Ernst & Young in 1998, MoneyWeb CEO of the Year in 2004, Sunday Times business leader of the year in 2010, and All Africa Businessman of the Year in 2016, among others. He appeared on the Forbes list of Africa’s 50 Richest in 2015.

We list these because they are dated and checkable, not because they bear on the valuation. They do not. An award is evidence that people admired a business at a point in time, which is a different claim from any made elsewhere on this page.

What we do not know

The current size of his shareholding, which needs reading out of the latest annual report rather than carried forward from an older one. What is held personally versus through trusts or family structures. What portion is encumbered, pledged or unvested. And what he holds outside Discovery, which is not disclosed in any form we can value.

If you can improve any of this with a public disclosure, tell us.